Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL ((R-HAD))

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2012 by European Mantle Cell Lymphoma Network.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Klinikum der Universitaet Muenchen, Grosshadern
ClinAssess GmbH
GELARC Service de Pharmacovigilance, Pierre Benite
Information provided by (Responsible Party):
Dr. M. Dreyling (co-chairman), European Mantle Cell Lymphoma Network
ClinicalTrials.gov Identifier:
NCT01449344
First received: September 28, 2011
Last updated: September 6, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2016
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)